Key result
Bempedoic acid cuts LDL-C by ~32% in older adults, matching efficacy in younger patients.
Why the study?
Does bempedoic acid reduce LDL cholesterol effectively and safely in older patients (≥70 years) compared to younger patients in a real-world setting?
Observational (n=80)
No
Does bempedoic acid reduce LDL cholesterol effectively and safely in older patients (≥70 years) compared to younger patients in a real-world setting?
Absolute Event Rate: 32% vs 37%
p-value: p=>0.05
Bempedoic acid is an effective and safe therapeutic option for managing dyslipidemia in older patients (≥70 years) in a real-world setting, with lipid-lowering efficacy comparable to younger patients.
Introduction Bempedoic acid (BA) is an inhibitor of adenosine triphosphate-citrate lyase that reduces cholesterol synthesis. Its current indication and funding are for patients who do not achieve their lipid goals despite maximum doses of statins and ezetimibe or those with intolerance/contraindication to these treatments. The aim of this study was to evaluate the effectiveness, safety, and adherence to BA treatment in a real-world older population. Material and Methods We conducted a descriptive, retrospective, single-centre observational study. Patients treated with BA from September 2023 to March 2024 were included. Patients were classified into two groups based on age (<70 and ≥ 70 years). Demographic, clinical, and analytical variables were analyzed. Effectiveness was assessed as the reduction in plasma LDL cholesterol levels and achievement of lipid goals (LDL cholesterol <55 mg/dL). Adherence was defined as the collection of at least 75% of the prescribed packages during the follow-up period. Adverse reactions (AR) were monitored during the follow-up. IBM-SPSS-Statistics was used for statistical analysis. Results A total of 80 patients were included (31 patients ≥70 years), most of whom started treatment with BA for secondary prevention. The main characteristics are summarized in the Table. Regarding baseline characteristics, there was a trend for higher statin intolerance in younger patients (42% vs 22%, p=0.06). There were no differences in lipid treatment before starting BA (statins >89%; ICPSK 8.2 vs 6.5%) or in treatment adherence between the two subgroups. Regarding cholesterol levels, BA treatment was associated with a similar reduction in both age groups (total cholesterol reduction 25% vs 20%, LDL cholesterol 37% vs 32%, non-HDL cholesterol 30% vs 20%, all p>0.05). The rate of AR during short-term follow-up was low (2%), with no differences between older and younger patients. Conclusions BA treatment in older patients is associated with a reduction in lipid parameters similar to that observed in younger populations, with a comparable safety profile. BA constitutes a new tool in the therapeutic arsenal for managing dyslipidemia in older patients.Table
No takes yet. Share an insight, caveat, or question.
Mendez et al. (2025) conducted an observational in Dyslipidemia (n=80). Bempedoic acid in older patients (≥70 years) vs. Bempedoic acid in younger patients (<70 years) was evaluated on Reduction in plasma LDL cholesterol levels (p=>0.05). Bempedoic acid treatment in older patients (≥70 years) reduced LDL cholesterol by 32%, similar to the 37% reduction seen in younger patients (<70 years) (p>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: